Literature DB >> 3303925

Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis.

M P Weinstein, C W Stratton, H B Hawley, A Ackley, L B Reller.   

Abstract

Forty-eight episodes of osteomyelitis, 30 acute and 18 chronic, were evaluated in a prospective multicenter collaborative study to determine whether a standardized serum bactericidal test could predict outcome of infection. All centers used a microdilution test method that defined the recognized important test variables, including inoculum size, culture medium, dilution technique, incubation time, method of subculture, and bactericidal endpoint. In patients with acute osteomyelitis, peak serum bactericidal titers had no predictive value; however, trough titers of 1:2 or greater accurately predicted cure, whereas trough titers of less than 1:2 predicted therapeutic failure. In patients with chronic osteomyelitis, peak serum bactericidal titers of 1:16 or greater and trough titers of 1:4 or greater accurately predicted cure, whereas peak titers of less than 1:16 and trough titers of less than 1:2 accurately predicted failure. It is concluded that this standardized serum bactericidal test provides good prognostic information in patients with osteomyelitis, and it is recommended that patients with acute osteomyelitis have serum bactericidal titers of 1:2 or greater at all times and that patients with chronic osteomyelitis have serum bactericidal titers of 1:4 or greater at all times.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3303925     DOI: 10.1016/0002-9343(87)90688-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Postoperative infections of the lumbar spine: presentation and management.

Authors:  Dennis S Meredith; Christopher K Kepler; Russel C Huang; Barry D Brause; Oheneba Boachie-Adjei
Journal:  Int Orthop       Date:  2011-12-10       Impact factor: 3.075

Review 3.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

4.  Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.

Authors:  Emmanuel Curis; Vincent Pestre; Vincent Jullien; Luc Eyrolle; Denis Archambeau; Philippe Morand; Laure Gatin; Matthieu Karoubi; Nicolas Pinar; Valérie Dumaine; Jean-Claude Nguyen Van; Antoine Babinet; Philippe Anract; Dominique Salmon
Journal:  Infection       Date:  2015-04-03       Impact factor: 3.553

Review 5.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

Review 6.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 8.  Osteomyelitis. Common causes and treatment recommendations.

Authors:  D R Dirschl; L C Almekinders
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

9.  Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.

Authors:  O Petitjean; B Pangon; N Brion; M Tod; C Chaplain; V Le Gros; K Louchahi; P Allouch
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.